Ensign Peak Advisors
PRAX icon

Ensign Peak Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Ensign Peak Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4M Buy
72,952
+4,569
+7% +$1.45M 0.04% 281
2026
Q1 		$22M Buy
68,383
+4,100
+6% +$1.27M 0.04% 292
2025
Q4 		$18.9M Buy
+64,283
New +$12M 0.03% 302
2025
Q1 		– Sell
-27,650
Closed -$2.13M – 1717
2024
Q4 		$2.13M Buy
+27,650
New +$2M ﹤0.01% 911
2022
Q2 		– Sell
-291
Closed -$45K – 2195
2022
Q1 		$45K Hold
291
– – ﹤0.01% 2136
2021
Q4 		$86K Buy
+291
New +$85.3K ﹤0.01% 2087

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ensign Peak Advisors's PRAX Position: Q2 2026 in Review

Ensign Peak Advisors increased its Praxis Precision Medicines (PRAX) stake by 6.7% in Q2 2026, buying an estimated $1.45M and bringing the position to 72,952 shares worth $24.4M. The position accounts for 0.04% of the portfolio, ranked #281.

Ensign Peak Advisors first reported a position in PRAX in Q4 2021 and has held it in 6 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Ensign Peak Advisors held 72,952 shares of Praxis Precision Medicines worth $24.4M as of Q2 2026.
  • Ensign Peak Advisors bought 4,569 Praxis Precision Medicines shares in Q2 2026, an estimated $1.45M.
  • Praxis Precision Medicines made up 0.04% of Ensign Peak Advisors's portfolio in Q2 2026, its #281 holding.
  • Ensign Peak Advisors first reported a position in Praxis Precision Medicines in Q4 2021 and has held it in 6 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.